Navigation Links
Proteolix Announces Clinical Results With Carfilzomib to be Reported at ASH 2007 Annual Meeting
Date:12/6/2007

SOUTH SAN FRANCISCO, Calif., Dec. 6 /PRNewswire/ -- Proteolix, Inc. announced today that data from two Phase 1 clinical studies using intravenous carfilzomib (PR-171) are to be presented at the 2007 American Society of Hematology (ASH) Annual Meeting in Atlanta, Georgia, December 8-10, 2007. Carfilzomib is a potent and selective proteasome inhibitor currently being investigated for the treatment of multiple myeloma, lymphoma and solid tumors.

Robert Z. Orlowski, M.D., Ph.D., of the University of Texas, M.D. Anderson Cancer Center, and Melissa Alsina, M.D., of the H. Lee Moffitt Cancer Center and Research Institute, will be presenting data from two Phase 1 clinical studies in relapsed and refractory hematologic malignancies on Monday, December 10 beginning at 11:00 am and 11:30 am EST, respectively, in a session entitled "Novel Therapies in Relapsed Myeloma." Additional information about the 2007 ASH Annual Meeting can be found on the ASH website at http://www.hematology.org/meetings/2007.

"We are very pleased that carfilzomib can be dosed on a consecutive-day schedule in humans, as was predicted by animal studies," said Susan M. Molineaux, Ph.D., President and CEO of Proteolix. "These early results showing single-agent activity in myeloma indicate the potential of this product candidate to help persons afflicted with the disease. We look forward to data throughout 2008 from ongoing Phase 1b and 2 studies in multiple myeloma, lymphoma and solid tumors."

About Proteolix

Proteolix, Inc. is a biopharmaceutical company dedicated to discovering, developing and marketing pharmaceutical products that target certain cancer and immunological conditions by inhibiting the proteasome and thereby disrupting protein turnover in cells. In addition to its lead product candidate, carfilzomib (PR-171), which is delivered intravenously and is currently in multiple clinical trials to evaluate its safety and efficacy in different types of cancer, Proteolix is developing next-generation proteasome inhibitors, including an oral proteasome inhibitor and a selective immunoproteasome inhibitor, to expand the therapeutic potential of this target class. Proteolix is headquartered in South San Francisco. For more information, please visit the Company's website at http://www.proteolix.com.

Contact: Stephen Brady, Executive Director of Business and Legal Affairs,

650-266-2621.


'/>"/>
SOURCE Proteolix, Inc.
Copyright©2007 PR Newswire.
All rights reserved

Related medicine news :

1. HHS Announces $75 Million in Supplemental Funding to States for Pandemic Flu Preparedness
2. CRC Health Group Announces Acquisition of Bayside Marin Recovery Center, San Rafael
3. UHW Announces: Antelope Valley Hospital Caregivers and Board Vote to Ratify First Union Contract With SEIU UHW-West
4. HEI, Inc. Announces Sale of RFID Division Assets
5. Caraco Pharmaceutical Laboratories, Ltd. Announces FDA Approval to Market Generic Version of Zyloprim(R)
6. Mettler-Toledo International Inc. Announces Webcast of Presentation at Thomas Weisel Partners 2007 Healthcare Conference
7. Z Trim Announces Revocation of Gregory Halpern Severence Agreement
8. Brooke Franchise Corporation Announces Selected July Results
9. Manor Care, Inc. Announces Record Date for Special Stockholder Meeting
10. Caraco Pharmaceutical Laboratories, Ltd. Announces FDA Approval to Market Generic Version of Adipex-P(R)
11. Planet Technologies Announces Agreement to Acquire Antigen Laboratories
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:10/13/2017)... ... October 13, 2017 , ... “America On The Brink”: the Christian history of ... Brink” is the creation of published author, William Nowers. Captain Nowers and his ... veteran, he spent thirty years in the Navy. Following his career as a ...
(Date:10/12/2017)... ... October 12, 2017 , ... ... treating sleep apnea using cutting-edge Oventus O2Vent technology. As many as ... disorder characterized by frequent cessation in breathing. Oral appliances can offer significant relief ...
(Date:10/12/2017)... ... 12, 2017 , ... The company has developed a suite ... regulatory authorities worldwide. From Children’s to Adults 50+, every formula has been developed ... , These products are also: Gluten Free, Non-GMO, Vegan, Soy Free, Non-Dairy*, ...
(Date:10/12/2017)... ... ... The American College of Medical Informatics (ACMI) will present the 2017 Morris ... of AMIA’s Annual Symposium in Washington, D.C. AMIA’s Annual Symposium is taking ... in the field of medical informatics, this prestigious award is presented to an individual ...
(Date:10/12/2017)... ... October 12, 2017 , ... Information about the technology: , ... to enable prevention of a major side effect of chemotherapy in children. Cisplatin ... patients. For cisplatin, hearing loss is FDA listed on-label as a dose limiting ...
Breaking Medicine News(10 mins):
(Date:10/12/2017)... , Oct. 12, 2017   Divoti USA ... Jewelry up to the standard of the latest FDA requirements, which ... 2017). Anyone in need of Medical ID jewelry such ... Alert Jewelry are engraved in terms of the new ... Divoti offers ...
(Date:10/11/2017)... 11, 2017  True Health, a leader in ... effort during National Breast Cancer Awareness month to ... Research recently ... that more than 10 million American women are ... BRCA1 or BRCA2 and have not had testing. These ...
(Date:10/7/2017)...   Provista, a proven leader in the ... purchasing power, today announced a new resource area on ... is the online home for case studies, articles ... news releases, slideshows and events. ... resources at their fingertips, viewers can also watch short ...
Breaking Medicine Technology: